http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 29 May 2026 06:50:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Press+Releases/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html <p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfDceobJgpZ_tY7mx78nL7PsRmk8WdVi9-ix9SzVxw-X1frJvdx_LOCuk2fnjsuvlCvyO2XymsAlcknAjCGxvSaHUbZ-huIwi0S-0BYQ5J1BGlQYauaL6v1pt5gQrWrljdQ8YYohhEm3oI2ZuriraAvLvrpc3F3-4wiEPgQhmBUrQpkNfui_7ZmVJ5l0GZqYwNtM=" rel="nofollow" target="_blank">Pharvaris</a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=lm_YVmdku5pPvI66FD6HYXGylyCubakQhurTS0-YHtJa87MrrSOYZCdwdzyrcb2pLoMsQygoOhnXH6HJVD9bGSjf8Keg1d2-ZuVbz0jpbi0uS3Jo-QTzfzXw9oA5OvxgidVqFE3n-ipr7525CyMHukQwmLEppiFZ0QPuERvB8ewMm2LzpRJAaceAlXtkXTFtqpRssyk8XcHsQ2hqSpqzvAeCAa46evF_3A42u9XrgoQ=" rel="nofollow" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026</a>, to be held from June 12-15, 2026, in Istanbul, Turkey.</p> <p>Details of http://www.streetinsider.com/Globe+Newswire/Pharvaris+to+Present+Clinical+Data+at+the+EAACI+Annual+Congress+2026/26570627.html Fri, 29 May 2026 06:50:00 -0400 A.37612190 A.50201579 O.12524441 O.25604838 O.29407519 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Monges+Viviane/26551542.html si-local-file:///var/storage/secattach/20260526/26551542.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Monges+Viviane/26551542.html Tue, 26 May 2026 17:53:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Monges+Viviane/26551542.html si-local-file:///var/storage/secattach/20260526/26551542.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Monges+Viviane/26551542.html Tue, 26 May 2026 17:53:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Nijdam+Anna/26551507.html si-local-file:///var/storage/secattach/20260526/26551507.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Nijdam+Anna/26551507.html Tue, 26 May 2026 17:45:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Nijdam+Anna/26551507.html si-local-file:///var/storage/secattach/20260526/26551507.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Nijdam+Anna/26551507.html Tue, 26 May 2026 17:45:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Nassif+David+W./26551494.html si-local-file:///var/storage/secattach/20260526/26551494.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Nassif+David+W./26551494.html Tue, 26 May 2026 17:42:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Nassif+David+W./26551494.html si-local-file:///var/storage/secattach/20260526/26551494.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+21++Filed+by%3A+Nassif+David+W./26551494.html Tue, 26 May 2026 17:42:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Nijdam+Anna/26542723.html si-local-file:///var/storage/secattach/20260522/26542723.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Nijdam+Anna/26542723.html Fri, 22 May 2026 17:03:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Nijdam+Anna/26542723.html si-local-file:///var/storage/secattach/20260522/26542723.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Nijdam+Anna/26542723.html Fri, 22 May 2026 17:03:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+20++Filed+by%3A+Bjork+Elisabeth/26540981.html si-local-file:///var/storage/secattach/20260522/26540981.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+20++Filed+by%3A+Bjork+Elisabeth/26540981.html Fri, 22 May 2026 14:54:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+20++Filed+by%3A+Bjork+Elisabeth/26540981.html si-local-file:///var/storage/secattach/20260522/26540981.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pharvaris+N.V.++++++++++++For%3A+May+20++Filed+by%3A+Bjork+Elisabeth/26540981.html Fri, 22 May 2026 14:54:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Pharvaris+N.V.++++++++++++For%3A+May+18++Filed+by%3A+Modig+Berndt/26540925.html si-local-file:///var/storage/secattach/20260522/26540925.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Pharvaris+N.V.++++++++++++For%3A+May+18++Filed+by%3A+Modig+Berndt/26540925.html Fri, 22 May 2026 14:41:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Pharvaris+N.V.++++++++++++For%3A+May+18++Filed+by%3A+Modig+Berndt/26540925.html si-local-file:///var/storage/secattach/20260522/26540925.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Pharvaris+N.V.++++++++++++For%3A+May+18++Filed+by%3A+Modig+Berndt/26540925.html Fri, 22 May 2026 14:41:00 -0400 O.25604838 PHVS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Nijdam+Anna/26537028.html si-local-file:///var/storage/secattach/20260521/26537028.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Pharvaris+N.V.+++++++++++++++++++++++++Filed+by%3A+Nijdam+Anna/26537028.html Thu, 21 May 2026 17:36:00 -0400 O.25604838 PHVS